Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03404193 · ClinicalTrials.gov registry record · Phase 2
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 235
- Enrollment target
NCT03404193: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT03404193 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 235 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03404193, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 235 participants
- Enrollment target
Study Summary
This phase II trial studies how well venetoclax and decitabine work in treating participants with acute myeloid leukemia that has come back or does not respond to treatment, or with high-risk myelodysplastic syndrome that has come back. Drugs used in chemotherapy, such as venetoclax and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Interventions
- DRUG Venetoclax
- DRUG Decitabine
- OTHER Laboratory Biomarker Analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 235 participants |
| Start Date | 2018-01-18 |
| Est. Completion | 2026-03-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03404193
The ClinicalTrials.gov registry entry for NCT03404193 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 235 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Venetoclax is the first listed.
NCT03404193 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03404193 about?
NCT03404193 is a clinical study titled "Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome". This phase II trial studies how well venetoclax and decitabine work in treating participants with acute myeloid leukemia that has come back or does not respond to treatment, or with high-risk myelodysplastic syndrome that has come back. Drugs used in chemotherapy, such as venetoclax and decitabine, ...
What is the current status of trial NCT03404193?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 235 participants. The study started on 2018-01-18. Estimated completion is 2026-03-05.
What interventions are being tested in trial NCT03404193?
The interventions under investigation include: Venetoclax (DRUG), Decitabine (DRUG), Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT03404193?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.